This company has no dividend history.
Based on TTM and annual data · Not a buy/sell signal
This company does not pay dividends
No dividend history found in SEC filings.
Does Renalytix (RENXF) pay a dividend?
Renalytix (RENXF) has never paid a dividend. Free cash flow is currently negative, so there is no surplus to distribute. All figures are computed from company filings; this is analysis, not investment advice.
Frequently asked
Does Renalytix (RENXF) pay a dividend?+
No. Renalytix (RENXF) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold.
How does Renalytix return cash to shareholders?+
It largely does not. Renalytix pays no dividend and we do not see a meaningful reduction in share count over the last twelve months, so cash is being retained in the business or spent on growth rather than returned. That is common for companies reinvesting heavily, and it means your return depends entirely on the share price.
Could Renalytix afford to pay a dividend?+
Not currently. Renalytix's free cash flow is negative at -$24 million, meaning the business consumed cash over the period rather than generating it. A company funding a dividend from cash it is not producing would be paying shareholders out of its balance sheet or borrowings, which is not sustainable.
Which healthcare companies do pay dividends?+
Our Healthcare sector page ranks the companies we cover by dividend score, which combines payout safety, free cash flow coverage and growth record. If income is what you are after, start there rather than with Renalytix.
SourceDividend analysis computed from the 10-Q filed 7 Nov 2024, covering the period ending 30 Sept 2024, as reported to the SEC. Data last refreshed 17 Aug 2026. How this is calculated.
Fiscal year ends Jun. Earnings payout = dividends / net income. FCF payout = dividends / FCF. Yield = TTM DPS / price.
Peers
Services-Medical Laboratories · Pick stocks to compare with RENXF
Spot a number that looks wrong? Check it in RENXF's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing RENXF
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.